Anderson E D, Forrest A P, Levack P A, Chetty U, Hawkins R A
University Department of Surgery, Royal Infirmary, Edinburgh, UK.
Br J Cancer. 1989 Aug;60(2):223-6. doi: 10.1038/bjc.1989.256.
Forty-three patients with large (greater than or equal to 4 cm) but operable carcinoma of the breast have been treated by endocrine manipulation before definitive local surgery. This has allowed the study of the relationship between response to therapy and pretreatment oestrogen receptor (ER) concentration, as measured by a dextran-coated charcoal adsorption method. Premenopausal patients (17) were treated by surgical (4) or medical (13) oophorectomy. Post-menopausal patients (26) received either tamoxifen (10) or an aromatase inhibitor (16). Response was assessed from statistical analysis of the changes in tumour size. On completion of 12 weeks of endocrine therapy, there was significant regression of tumour size in 18 of the 43 patients. All 18 patients had tumours with ER concentrations of greater than or equal to 20 fmol mg-1 cytosol protein. Conversely all patients except one progressing on treatment had tumours with ER concentrations of less than 20 fmol mg-1 cytosol protein. This relationship applied for both premenopausal and post-menopausal patients. The overall response rate of patients with tumours of ER concentration greater than or equal to 20 fmol mg-1 cytosol protein was 60%.
43例患有大型(大于或等于4厘米)但可手术切除的乳腺癌患者在进行确定性局部手术前接受了内分泌治疗。这使得能够研究通过葡聚糖包被活性炭吸附法测定的治疗反应与治疗前雌激素受体(ER)浓度之间的关系。绝经前患者(17例)接受了手术(4例)或药物(13例)卵巢切除术。绝经后患者(26例)接受了他莫昔芬(10例)或芳香化酶抑制剂(16例)治疗。通过对肿瘤大小变化的统计分析来评估反应。在内分泌治疗12周结束时,43例患者中有18例肿瘤大小出现显著缩小。所有18例患者的肿瘤ER浓度均大于或等于20 fmol mg-1细胞溶质蛋白。相反,除1例在治疗中病情进展的患者外,所有病情进展的患者肿瘤的ER浓度均低于20 fmol mg-1细胞溶质蛋白。这种关系在绝经前和绝经后患者中均适用。ER浓度大于或等于20 fmol mg-1细胞溶质蛋白的肿瘤患者的总体反应率为60%。